LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against United Therapeutics Corporation (“United Therapeutics” or the “Company”) (Nasdaq: UTHR) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at firstname.lastname@example.org.
On July 27, 2017, United Therapeutics revealed that it recorded a $210 million accrual relating to a potential settlement in connection with a Department of Justice investigation into the Company’s possible violations of the Federal Anti-Kickback Statute and the Federal False Claims Act. Upon release of this information, shares of United Therapeutics fell in value.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.